Methodist Debakey Cardiovasc J. 2026 Sep 15;22(4):102-105. doi: 10.14797/mdcvj.1955. eCollection 2026.
ABSTRACT
Genetic testing is the step most often omitted once a cardiomyopathy has been characterized and the step most often misapplied when it is extended to people who have no phenotype. I describe a 68-year-old African American man with transthyretin amyloid cardiomyopathy who had none of the classic red flags, and use his case to define who should be tested, what must be excluded first, and what the result changes.
PMID:42761942 | PMC:PMC13588222 | DOI:10.14797/mdcvj.1955